Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Citi
UBS
Cerilliant
Merck
Johnson and Johnson
Dow
Baxter
QuintilesIMS

Generated: July 15, 2018

DrugPatentWatch Database Preview

EUCRISA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Eucrisa patents expire, and when can generic versions of Eucrisa launch?

Eucrisa is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and eleven patent family members in twenty-two countries.

The generic ingredient in EUCRISA is crisaborole. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.
Summary for EUCRISA
International Patents:111
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 56
Clinical Trials: 2
Patent Applications: 30
DailyMed Link:EUCRISA at DailyMed
Drug patent expirations by year for EUCRISA
Generic Entry Opportunity Date for EUCRISA
Generic Entry Date for EUCRISA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
OINTMENT;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EUCRISA
Synonyms for EUCRISA
1073669-75-6
1187189-21-4
4-((1-HYDROXY-1,3-DIHYDROBENZO-[C][1,2]OXABOROL-5-YL)OXY)BENZONITRILE
4-((1-Hydroxy-1,3-dihydrobenzo(c)(1,2)oxaborol-6-yl)oxy)benzonitrile
4-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile
4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)benzonitrile
4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile
4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile
5-(4-cyanophenoxy)-1-hydroxy-2,1-benzoxaborole
5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole
5098AC
906673-24-3
ABP001114
AK102641
AKOS016005425
AN 2728
AN-2728
AN2728
ANW-65536
API0013781
AX8234180
BC245091
BDBM50277665
Benzonitrile, 4-((1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy)-
Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]-
C14H10BNO3
CHEBI:134677
CHEMBL484785
compound 5b [PMID: 19303290]
Crisaborole
Crisaborole (USAN/INN)
Crisaborole [USAN:INN]
Crisaborole topical ointment 2%
Crisaborole, >=98% (HPLC)
Crisaborole(AN-2728)
CS-1057
CTK8C0958
D0SM0W
D10873
DB-078771
DB05219
DTXSID10238231
Eucrisa (TN)
EX-A1087
FT-0767999
GTPL9151
HE053309
HE268247
HY-10978
KB-40872
KS-0000063U
MFCD17169940
MolPort-023-332-548
NCGC00345792-01
Q2R47HGR7P
SCHEMBL595261
ST24042710
TC-154281
UNII-Q2R47HGR7P
USZAGAREISWJDP-UHFFFAOYSA-N
W-5676
ZINC169748244

US Patents and Regulatory Information for EUCRISA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for EUCRISA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,889,656 Boron-containing small molecules ➤ Sign Up
7,582,621 Boron-containing small molecules ➤ Sign Up
9,566,289 Boron-containing small molecules ➤ Sign Up
9,566,290 Boron-containing small molecules ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Cantor Fitzgerald
Boehringer Ingelheim
UBS
Argus Health
Covington
QuintilesIMS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.